Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule.
Healthy subjects (15-50 years old) were randomised to receive, intramuscularly, 10 or 20 micrograms of a yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) on a two-dose (0-1) schedule. Anti-hepatitis B surface antigen antibodies (HBsAb) were determined at 2, 3 and 6 months. Twenty micrograms immunisation yielded 96.3% seroprotection (HBsAb >10 IU/l) at t=3, which persisted to 97.2% at t=6. The 10 microgram group resulted in 87.4% seroprotection at t=3 and 81% at t=6, but reached >95% among subjects <21 years old, both at t=3 and 6. It is concluded that the vaccine used is highly immunogenic and the two-dose 20 microgram immunisation can be used in all age groups and 10 micrograms in subjects up to 20 years. These schedules can result in significantly better compliance and cost-effectiveness of the vaccination programs.
ul-Haq
Najib
N
Khyber Medical College, Pakistan R-4, University Campus, North West Frontier Province, Peshawar, Pakistan. najibulhaq@psh.paknet.pk
Hasnain
Syed S
SS
Umar
Muhammad
M
Abbas
Zaigham
Z
Valenzuela-Silva
Carmen
C
Lopez-Saura
Pedro
P
D000293:Adolescent; D000328:Adult; D000375:Aging / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis / Q000096:biosynthesis; D006514:Hepatitis B Surface Antigens / Q000032:analysis / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000276:immunology; D011446:Prospective Studies; D014614:Vaccines, Synthetic / Q000276:immunology
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic